2022
Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention
Cadamuro M, Strazzabosco M. Inflammatory pathways and cholangiocarcioma risk mechanisms and prevention. Advances In Cancer Research 2022, 156: 39-73. PMID: 35961707, PMCID: PMC10916841, DOI: 10.1016/bs.acr.2022.02.001.Peer-Reviewed Original ResearchConceptsDevelopment of cholangiocarcinomaNonalcoholic fatty liver diseaseAdequate therapeutic treatmentPrimary sclerosing cholangitisFatty liver diseasePro-inflammatory mechanismsMain risk factorsProdromal diseaseSclerosing cholangitisCaroli's diseaseMetabolic syndromeChronic cholangiopathiesLiver diseasePoor prognosisInflammatory pathwaysBiliary treeCCA developmentRisk factorsImmune responseImmunological responseTherapeutic targetCholangiocarcinomaFluke infestationRole of cellExtrahepatic areas
2021
Unmet needs in basic and translational research in Cholangiocarcinoma
Cadamuro M, Macias R, Strain A, Strazzabosco M, Simioni P, Marin J, Fabris L. Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International 2021, 3: 5-16. DOI: 10.1002/lci2.39.Peer-Reviewed Original ResearchTranslational researchManagement of cholangiocarcinomaTumor-restraining functionsSystematic literature searchCCA managementPoor prognosisExtrahepatic cholangiocarcinomaDeep molecular phenotypingConsensus statementEnigmatic diseaseActionable mutationsCholangiocarcinomaAccurate biomarkersTumor microenvironmentLiterature searchExperimental modelEarly detectionMarked heterogeneityDiseaseMolecular phenotypingWide heterogeneityFurther studiesTumorsMolecular characterization studiesComplex role
2017
Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview
Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. Gene Expression 2017, 18: 31-50. PMID: 29070148, PMCID: PMC5860940, DOI: 10.3727/105221617x15088670121925.Peer-Reviewed Original ResearchConceptsMajority of patientsPrimary liver cancerCancer-related deathPotential prognostic relevanceDevelopment of metastasesPro-oncogenic pathwaysNovel druggable targetsMechanism of actionCholangiocarcinoma invasivenessMesenchymal-like phenotypeDevastating malignancyCurative treatmentMolecular mechanismsPoor prognosisPrognostic relevancePrimary tumorBiliary epitheliumLiver cancerUseful biomarkerAbnormal activationCCA cell invasionMost carcinomasCCA cellsTumor microenvironmentCholangiocarcinoma
2011
Nuclear expression of S100A4 calcium‐binding protein increases cholangiocarcinoma invasiveness and metastasization
Fabris L, Cadamuro M, Moserle L, Dziura J, Cong X, Sambado L, Nardo G, Sonzogni A, Colledan M, Furlanetto A, Bassi N, Massani M, Cillo U, Mescoli C, Indraccolo S, Rugge M, Okolicsanyi L, Strazzabosco M. Nuclear expression of S100A4 calcium‐binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology 2011, 54: 890-899. PMID: 21618579, PMCID: PMC3753582, DOI: 10.1002/hep.24466.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnimalsApoptosisBile Duct NeoplasmsBile Ducts, IntrahepaticCell MovementCell NucleusCell ProliferationCholangiocarcinomaFemaleHumansMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9MiceMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisPrognosisS100 Calcium-Binding Protein A4S100 ProteinsConceptsSurgical resectionCCA cellsNuclear expressionCCA patientsMetastatic propertiesSevere combined immunodeficiency miceTFK-1Time of surgeryRole of S100A4Log-rank testCombined immunodeficiency miceExpression of S100A4EGI-1 cellsHuman CCA cell linesPotential therapeutic targetMMP-9 secretionCCA cell linesHuman liver samplesCholangiocarcinoma invasivenessNuclear S100A4Severe prognosisPatient survivalPoor prognosisNeoplastic ductsImmunodeficiency mice